07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
07:00 , May 2, 2011 |  BioCentury  |  Finance

Familiarity breeds content

European life sciences firm LSP raised €36 million ($52.5 million) last week in an IPO for its first in-house fund to invest in public companies. The firm is capitalizing on investors' familiarity with its venture...
02:23 , Dec 17, 2008 |  BC Extra  |  Financial News

OncoMethylome raises EUR 8.4 million

Molecular diagnostics company OncoMethylome (Euronext:ONCOB) raised EUR 8.4 million ($11.3 million) through a private placement of 1.3 million shares at EUR 6.29. The deal price is a 4% premium to OncoMethylome's close of EUR 6.05...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Midlife crisis

Investor enthusiasm for European biotech is falling away just as the industry's capital demand continues to rise in response to a plethora of maturing clinical programs. Investors are shying away from mid-stage companies, preferring either...
07:00 , May 5, 2008 |  BioCentury  |  Finance

Ebb & Flow

Publicly quoted European biotechs, beaten down by tough capital market conditions, will take some comfort from last week's news that the Netherlands' largest pension group is committed to increasing its focus on small-cap life science...
01:09 , Apr 29, 2008 |  BC Extra  |  Financial News

LSP, APG unveil partnership

LSP (Life Sciences Partners) formed a strategic investment relationship with Dutch pension asset manager APG Investments to invest in small-cap European biotechs. APG has more than EUR 200 billion ($311.9 billion) under management, while LSP...